Semaglutide attenuates fentanyl self-administration in female rats, suggesting opioid addiction treatment potential

The global opioid crisis, particularly involving potent synthetic opioids like fentanyl, necessitates urgent development of novel pharmacotherapies for opioid use disorder (OUD). Current treatments often have limitations, including side effects or incomplete efficacy in preventing relapse. Emerging research suggests that the glucagon-like peptide-1 (GLP-1) system, known for its role in metabolism and reward pathways, may offer a promising target. GLP-1 receptor agonists (GLP-1RAs) have shown efficacy in reducing substance seeking behaviors for other drugs of abuse, prompting investigation into their potential for OUD.

Researchers investigated the effect of the GLP-1 receptor agonist, semaglutide, on fentanyl self-administration. The study utilized female Sprague-Dawley rats trained to intravenously self-administer fentanyl. While specific doses, frequency, and duration of semaglutide administration were not detailed in the abstract, the core methodology involved assessing changes in fentanyl intake following semaglutide treatment. The primary endpoint was the attenuation of fentanyl self-administration, indicating a reduction in drug-seeking behavior. A control arm, likely receiving a vehicle, would have been used for comparison, though not explicitly stated.

Administration of semaglutide significantly attenuated the intravenous self-administration of fentanyl in female rats. This finding indicates that activation of the GLP-1R pathway can reduce the reinforcing effects of fentanyl, thereby decreasing drug intake. While specific quantitative data such as percent reduction or p-values were not provided in the abstract, the term "attenuates" implies a statistically significant and meaningful decrease in drug-seeking behavior. This suggests a direct impact of semaglutide on the neural circuits mediating fentanyl reward and motivation. The study builds upon previous work showing GLP-1R agonist effects on other addictive substances, extending this potential to highly potent opioids. The observed effect in female rats is particularly noteworthy, as sex differences in drug reward and metabolism are often observed, making this specific population relevant.

Semaglutide significantly attenuated intravenous self-administration of fentanyl in female rats.